Drug Database
PA

parathyroid hormone (Natpara / NPSP558 / SHP634)

✓ Approved

AstraZeneca UK Limited · PTH1R · Recombinant Proteins

What is parathyroid hormone?

parathyroid hormone is a recombinant proteins developed by AstraZeneca UK Limited. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.

Drug Profile

Brand NamesNatpara, NPSP558, SHP634
CompanyAstraZeneca UK Limited
Drug ClassRecombinant Proteins
Molecular TargetPTH1R
RouteInjectable (Others), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, AstraZeneca UK Limited

Mechanism of Action

Molecular Targets

parathyroid hormone acts on 1 molecular target:

PTH1Rparathyroid hormone 1 receptor (PTHR, EKNS)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

parathyroid hormone is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Endocrine disordersHypoparathyroidism✓ Approved
Musculoskeletal and connective tissue disordersOsteoporosis✓ Approved

Related Research Articles

PubMedKidney medicine2026-08-30

Calcium Crystal Deposits in Kidney Allografts: The Interplay of PTH Levels and Phosphaturia.

Barbuto Simona S, Vischini Gisella G, Magagnoli Lorenza L, Provenzano Michele M et al.

Hyperparathyroidism is common in kidney transplant recipients and may contribute to graft injury through calcium crystal deposition. We investigated the association between pretransplant parathyroid hormone (PTH) levels and calcium crystal deposits (CCDs) and whether fractional excretion of phosphate (FePi) mediates this relationship. Retrospective single-center observational study. Forty-one kidney transplant recipients undergoing protocol biopsies at 3 and 12 months posttransplantation. Pretransplant PTH levels. Presence of calcium crystal deposits in graft biopsies. Logistic regression models and mediation analysis were used to evaluate associations between PTH levels, FePi, and CCDs. CCDs were detected in 33% of biopsies at 3 months and 45% at 12 months. Higher pretransplant PTH levels were associated with increased odds of CCDs. Mediation analysis showed that approximately 72% of this effect was explained using FePi levels. At 24 months posttransplantation, no meaningful difference in estimated glomerular filtration rate was observed between patients with and without CCDs. Retrospective design, small sample size, absence of fibroblast growth factor 23 level measurements, and limited adjustment for potential confounders. Elevated pretransplant PTH levels are associated with calcium crystal deposition in kidney allografts, largely mediated by phosphate wasting. However, no clear impact on graft function was observed within the first 2 years posttransplantation.

PMID 42668546
Read full article →
PubMedAutophagy2026-08-30

Thyroid hormone promotes lipid droplet remodeling and lipophagy through KAT2B/PCAF-dependent histone acetylation in preimplantation embryos.

Lee Song-Hee SH, Zhan Cheng-Lin CL, Cui Xiang-Shun XS

Thyroid hormones are central regulators of metabolic homeostasis and developmental programming. The active hormone triiodothyronine (T3) modulates transcription through nuclear receptors that recruit epigenetic cofactors to remodel chromatin and regulate metabolic gene networks. Although thyroid hormone signaling is known to influence lipid metabolism, whether it coordinates lipid droplet turnover with autophagy-related pathways during early embryonic development remains largely unknown. Here, transcriptomic profiling revealed distinct metabolic signatures between in vivo and in vitro embryos, with marked differences in fatty acid metabolism. Supplementation with 50 nM T3 enhanced blastocyst formation, particularly when applied from the 4-cell to blastocyst stages, coinciding with elevated thyroid hormone receptor expression. T3 induced robust lipid droplet remodeling, characterized by reduced droplet size, together with increased lipid-mitochondria colocalization and activation of lysosomal and mitochondrial pathways, consistent with enhanced lipid catabolism and organelle coupling. Mechanistically, inhibition of the histone acetyltransferase KAT2B/PCAF abolished T3-mediated developmental gains, reduced H3K9ac and H3K27ac, and resulted in nonselective autophagic stress rather than lipophagy. By contrast, T3 required KAT2B to stimulate cytosolic lipolysis, channel fatty acids into mitochondria, and enhance mitochondrial membrane potential. T3 also upregulated prostaglandin biosynthesis genes and improved outgrowth performance. These findings identify a thyroid hormone-KAT2B epigenetic axis that coordinates lipid droplet remodeling through lipolytic and lipophagic pathways, linking endocrine signaling to organelle crosstalk and mitochondrial activation during early embryogenesis.

PMID 42669119
Read full article →
PubMedCancer causes & control : CCC2026-08-30

Effect of the SARS-CoV-2 pandemic on the opportunity to treat patients with breast cancer: experience at a reference cancer center in Mexico City.

Cruz-Badillo Blanca Margarita BM, García-Arango Caleb C, Aldama-Santos Ixtayul Leopoldo IL, Cuapantecatl-Hernandez Laura Denisse LD et al.

Delays from diagnosis to first treatment are a persistent challenge in Mexico. Retrospective observational cohort at the National Cancer Institute (INCAN), Mexico City (November 2017-December 2021). Women with first-time breast cancer and complete dates for diagnosis and treatment start were included. Primary outcome was diagnosis-to-treatment interval (DTI) in days; timeliness was defined as initiation ≤ 30 days. Bivariate tests and multivariable logistic regression were used (two-sided α = .05). We included 425 women. Median DTI was 18 days (IQR 14-24) among timely cases and 42 days (IQR 35-55) among delayed cases. By care period, median DTI was 28 days pre-pandemic and 23.5 days during the pandemic; the proportion initiating ≤ 30 days was similar (58.7 vs 61.9%; P = .509). In bivariate analysis (Supplementary Table S1), timeliness differed by initial treatment-chemotherapy and hormone therapy showed higher odds than surgery (global P< .001)-and high socioeconomic status had lower odds versus low status (OR, 0.36; 95% CI, 0.14-0.96; P = .042); the care period was not significant (P = .509). In multivariable models, pandemic care was associated with lower odds of timeliness (aOR, 0.54; 95%  CI, 0.33-0.88; P = .014); starting with chemotherapy (aOR, 19.77; 95%  CI, 5.23-74.62; P <.001) or hormone therapy (aOR, 2.79; 95% CI, 1.14-6.85; P = .024) increased the odds; each additional day from first consultation to referral to medical oncology reduced the odds (per-day OR, 0.99; 95% CI, 0.98-0.99; P = .005). A subset of patients experienced clinically relevant delays. Despite similar ≤ 30-day proportions across periods, pandemic care was independently linked to reduced timeliness after adjustment. Streamlined referral and process optimization are priorities to preserve timely access under system stress. In a tertiary center in Mexico City, the diagnosis-to-treatment interval was substantially shorter for patients initiating chemotherapy or hormone therapy than for those starting with surgery. Each additional day from first consultation to referral to medical oncology reduced the odds of meeting the ≤ 30-day target. Focusing on referral logistics and early treatment decision points can preserve timeliness under system stress and can be implemented without new infrastructure, informing pragmatic pathways in similar middle-income settings.

PMID 42668293
Read full article →
PubMedDrug and alcohol dependence reports2026-08-30

Exploring hormonal influences on nicotine craving and use across the perinatal period: A prospective longitudinal study.

Allen Alicia M AM, Baurley James J, Linde-Krieger Linnea B LB, Chalke Arushi A et al.

Perinatal nicotine use is common despite well-documented adverse consequences. We examined associations between reproductive-related hormones with nicotine craving and use during the perinatal period to identify potential novel intervention points. All participants reported use of nicotine during the perinatal period. Participants were enrolled at gestational week ≥ 36 and followed to postpartum week 12 via daily surveys (i.e., nicotine craving via 100-point scale, dichotomous use) and weekly hormone measurement in saliva (cortisol, oxytocin) or dried blood spots (progesterone, estradiol, testosterone, dehydroepiandrosterone sulfate). Bayesian mixed-effects models accounted for within-person correlation while estimating hormone effects. Participants (n = 46) were 28.9 ± 4.9 years old. During follow-up, exclusive combustible cigarettes (n = 20), electronic nicotine delivery systems (ENDS; n = 13), or dual (n = 2) use was observed, with variability in use and craving across participants and over time. During pregnancy, higher oxytocin was linked to greater craving (β=16.31, 95% CI: 3.71, 28.83). Greater peripartum declines in oxytocin were associated with more craving (β=8.71, 95% CI: 0.75, 16.93) and use (β=1.13, 95% CI: 0.05, 2.43). During postpartum, lower estradiol was linked to more craving (β=-1.17, 95% CI: -2.15, -0.18) and use (β=-0.40, 95% CI: -0.76, -0.03). In models simultaneously evaluating all postpartum hormones, the lone meaningful association was between estradiol and craving (β=-1.66, 95% CI: -2.84, -0.48). The results of this study suggest that oxytocin and estradiol may contribute to the risk of perinatal nicotine use. Additional research is needed to replicate our observations in more diverse study samples and explore implications for clinical intervention.

PMID 42668554
Read full article →
PubMedComparative biochemistry and physiology. Toxicology & pharmacology : CBP2026-08-30

Impact of propylthiouracil-induced thyroid hormone deficiency on reproduction and larval development in Japanese medaka (Oryzias latipes).

Wada Kohei K, Ogata Keiko K, Tanaka Hitoshi H

Thyroid hormone (TH) system disruption in aquatic organisms is a major global concern, yet links between laboratory toxicity data and population-level impacts remain unclear. Here, we investigated the effects of chemically induced TH deficiency on population-relevant apical endpoints-growth, development, and reproduction-in Japanese medaka (Oryzias latipes). Medaka were exposed to propylthiouracil (PTU), a TH synthesis inhibitor, in a 21-day short-term reproduction assay and a 47-day partial life-cycle test. This approach enabled the evaluation of effects across multiple life stages and generations. PTU exposure led to reduced TH levels, thyroid histopathological changes, and upregulation of TH-related genes, confirming the sensitivity of these endpoints in medaka. In offspring from the TH-deficient group, delayed hatching and reduced growth were detected. However, investigation of larval-juvenile metamorphosis and development of the swim bladder and retina showed limited or no effects, despite their established association with TH. While reproductive output and vitellogenin levels were unaffected even under TH depletion, reduced secondary sexual characteristics in adult males and delayed testicular development in offspring were observed. These results suggest possible crosstalk between thyroid and reproductive axes, although non-specific systemic toxicity cannot be excluded. These findings indicate that TH-responsive molecular and organ-/tissue-level endpoints are not necessarily directly relevant to population-level adverse outcomes and should be interpreted carefully. Overall, this study supports the utility of medaka as a model for evaluating thyroid active substances and highlights the importance of a weight-of-evidence approach integrating diverse endpoints for the assessment of endocrine-disrupting chemicals in aquatic environments.

PMID 42669389
Read full article →
PubMedCureus2026-08-30

Multisystem Benefits of GLP-1 Microdosing: A Narrative Review.

Panlilio Mia A MA, Piserchio Natalie N, Hennessey Mercedes M, Torres Kayla K et al.

Glucagon-like peptide-1 (GLP-1) is an endocrine hormone that plays a role in lowering blood glucose levels and promoting weight loss. GLP-1 receptor agonists (GLP-1 RAs) are synthetic peptides that mimic the activity of GLP-1, and the recent development of GLP-1 RA medications has been a major historical advancement in the treatment of diabetes and obesity. Despite the rapid development of GLP-1 RA medications, there is a very high demand for the limited supply of these drugs, resulting in high medication costs and significant care gaps among prescribed patients. This shortage has forced providers to be more strategic and creative with their treatments in order to support therapeutic continuity, which has led to an increased utilization of medication microdosing. This article aims to summarize available evidence on the effects of GLP-1 RAs and the possible benefits of long-term microdosing GLP-1 RA medications.

PMID 42668762
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about parathyroid hormone